Ir a las Transacciones
Salud | TMT

ScreenPoint Medical has raised US$28 million in a Series C investment round led by Insight Partners

Netherlands-based ScreenPoint Medical, an AI technology company that develops advanced image recognition and machine learning software to improve early detection of breast cancer, has raised US$28 million (€24 million) in a Series C funding round led by New York-based global venture capital and private equity firm Insight Partners to further develop its technology and accelerate commercial growth of the company’s Transpara AI breast care software.

Founded in 2014 by Professor Nico Karssemeijer and Professor Sir Michael Brady and based in Nijmegen, the Netherlands, ScreenPoint Medical develops and markets innovative machine learning solutions to improve breast cancer screening and diagnosis. With its market-leading AI solution Transpara, ScreenPoint Medical supports radiologists in evaluating mammograms to detect breast cancer and allows them to improve the quality and efficiency of breast cancer screening. Transpara is currently used in over 200 clinics in 25 countries worldwide.

Insight Partners is a US-based venture capital and private equity firm with more than US$30 billion in capital commitments. With its experience and track record of investing in high-growth technology and software companies that drive transformative change in their industries, Insight Partners is ideally situated to support ScreenPoint Medical with its endeavors. Alongside Insight Partners, University Radiology Group, one of the largest providers of sub-specialty radiology and teleradiology services in the United States, participated in the investment round. Existing investors, including ScreenPoint Medical’s founders Siemens Healthineers and Oost NL, will continue to support the company in its further growth and development.

Oaklins’ team in the Netherlands acted as the exclusive advisor to the shareholders and management of ScreenPoint Medical.

About ScreenPoint

ScreenPoint was founded in 2014 as a spin-off from Radboud University Medical Center in Nijmegen, the Netherlands, to develop and bring to market innovative machine learning solutions to improve breast cancer screening and diagnosis. With an exceptional team of specialists in machine learning, image analysis and breast imaging, ScreenPoint developed the market-leading AI solution Transpara for reading mammograms and breast tomosynthesis.

About Insight Partners

Insight Partners is a leading global venture capital and private equity firm investing in high-growth technology and software ScaleUp companies that are driving transformative change in their industries. Founded in 1995, Insight Partners has invested in more than 400 companies worldwide and has raised through a series of funds more than US$30 billion in capital commitments. Insight's mission is to find, fund and work successfully with visionary executives, providing them with practical, hands-on software expertise to foster long-term success. Across its people and its portfolio, Insight encourages a culture around a belief that ScaleUp companies and growth create opportunity for all.

“We are delighted to welcome Insight Partners as a new shareholder of ScreenPoint Medical. Their broad experience and network within the medical technology sector will enable us to further develop and commercialize our AI solution. The support and guidance of the Oaklins team, together with their experience in the medical imaging space, has proven extremely valuable throughout this process.”

Nico Karssemeijer

Founder and CEO

Contáctese con el equipo de la transacción

Robert Boersma

Socio
Amsterdam, Países Bajos
Oaklins Netherlands

Martijn de Win

Director
Amsterdam, Países Bajos
Oaklins Netherlands

Robbert Bon

Asociado Senior
Amsterdam, Países Bajos
Oaklins Netherlands

Transacciones relacionadas

Bayer AG has entered into a takeover agreement with Cara Care
Salud | TMT

Bayer AG has entered into a takeover agreement with Cara Care

Bayer AG, renowned for its advancements in healthcare and life sciences, has finalized the acquisition of Cara Care (HiDoc Technologies GmbH), which entered debtor-in-possession proceedings in October 2024. Cara Care, an innovative digital health platform and official DiGA, aligns perfectly with Bayer’s strategic focus on digital health and the expansion of its innovative solutions portfolio. The transaction is expected to close in Spring 2025.

Aprenda más
Grupo Veta 2017 S.L. has been acquired by MSA Mizar
Private Equity | Servicios de Soporte Comercial | Servicios Financieros | TMT

Grupo Veta 2017 S.L. has been acquired by MSA Mizar

The Franco-Belgian fund Kartesia has sold Grupo Veta 2017 S.L. to the Italian group MSA Mizar. Kartesia, the main shareholder of Veta+ together with its founding partner, has sold 100% of the capital. For MSA Mizar, this transaction represents the consolidation of its presence in Spain, the entry into the multi-risk claims management market and the opportunity to apply Veta+’s expertise to other European markets.

Aprenda más
Amber-Allen Publishing has sold its publishing assets to Penguin Publishing Group
TMT

Amber-Allen Publishing has sold its publishing assets to Penguin Publishing Group

Amber-Allen Publishing, home to some of the world’s most influential personal development books, most notably “The Four Agreements” by Don Miguel Ruiz and Janet Mills, has sold its publishing assets to Penguin Publishing Group. When the acquisition is complete, the Amber-Allen list will be managed by the TarcherPerigee imprint.

Aprenda más